智慧財產權月刊 216 期

9 /104

9
本月專題
我國藥品專利保護之現況與未來——從專利連結制度之研擬談起
105.12 智慧財產權月刊 VOL.216
11 ᖹԫج ୋ 20 ૢୋ 2 ಛʿୋ 21 ૢୋ 2 ಛਞ๫f
12 European Commission, Pharmaceutical Sector Inquiry Final Report, Jul. 8 , 2009 , at 449
(available at
paper_part1.pdf, last visited 15 October 2016).
13 ༉୚ীሞਞԈ JAHN R. THOMAS, PHARMACEUTICAL PATENT LAW 38-49 (2005); PHILIP
W. GRUBB & P ETER R. THOMSEN, PATENTS FOR CHEMICALS, P HARMACEUTICALS
AND BIOTECHNOLOGY 250-265 (5th 2010).
14 Schulte/Moufang, PatG, 8. Aufl., Köln, 2008, ² 1 Rdnr. 244.
15 Էνjʊٝ͜׵ݑ ࣘ٭אࣘʘ A+B ଡ଼ϓيdෛ೯ܝତՈϞ X ᔼᐕࣖ؈dΪϾ˸ A+B ଡ଼ϓي
͜׵ط ᐕ X शषʘᔼᐕ͜௄͡ሗਖ਼лfSchulte/Moufang, a.a.O. (FN 14), ² 1 Rdnr. 251.
16 Էνjʊٝ A+B ଡ଼ϓي ՈϞ X ᔼᐕ͜௄dෛ ೯ܝତՉ࿁ Y शषՈϞᔼᐕࣖ؈dΪϾ˸ A+B
ଡ଼ϓي ͜׵ط ᐕ Y शषʘᔼᐕ͜௄Ύ͡ሗਖ਼лfSchulte/Moufang, a.a.O. (FN 14), ² 1 Rdnr.
255; JAHN R. T HOMAS, PHARMACEUTICAL PATENT LAW 45 (2005).
17 ຾᏶௅౽ᅆৌପ҅€ 2009dਖ਼лᄲݟ ਿ๟‘dࠫ 2-10-26f
18 ੵʠ̻€2001 ϋd”̨ᝄʕণᖹਖ਼л ڭ ᚐʘΫᚥၾۃ ᓼ€ɨ•d౽ᅆৌପᛆ‘d36 ಂdࠫ
14-15i Schulte/Moufang, a.a.O. (FN 14), ² 1 Rdnr. 254.
of the drugʿՉଡ଼ϓ€a composition of matterʘ ي ሯ€ substanceeଡ଼Υ ي
€compositionאৣ˙€formulation ഃيʘ೯׼d͡ሗਖ਼лڭᚐf
（一）延續性藥品發明之重要性
͡ሗਖ਼лڭᚐʘᅺٙ߰މᖹۜʘϞࣖϓʱ 11dʔሞՉيމሯeଡ଼Υي
א ৣ˙೯׼dո್Ϟࡘʚਖ਼лʘ̙ঐfৰϤʘ̮dʔ˶ᖹۜਖ਼лࣩڷ ఱ
ʊٝᖹۜආБҷԄא޼೯Ͼପ͛อٙᔼᖹ೯׼dኪଣɪϞ၈ މ˜ַᚃ׌
ਖ਼뙈secondary patents12fϤഃ೯׼ʘlz࢙ɗ০࿁ʊٝᖹۜϞࣖϓʱ
ʘอᔼᐕࣖ ؈dܼ̍อቇᏐसeอيଣഐ࿴€ new physical formeᖹۜ
୐ɿɽʃ€ particle sizeeኒۨ א ኒඎ€dosagee ݺ ׌˾ᑽي€active
metaboliteeՇ၇˸ɪᖹۜଡ଼ΥאΥԻԴ͜ʘᔼᖹଡ଼ϓאيԴ͜˙ό 13f
˸อቇᏐसᖹۜ೯׼މ ԷdఱʊٝᖹۜʘϞࣖϓʱᐏ઄อٙطᐕቇ
Ꮠसd੻˸༈อᔼᐕ͜௄ މᅺٙ͡ሗਖ਼л 14dኪଣɪ၈މୋɓᔼᐕ͜௄
€first pharmaceutical use15 אୋɚᔼᐕ͜௄€second pharmaceutical use
ʘ೯׼ 16fอᔼᐕ͜௄ਖ਼лʘᛆлᇍఖࠢ׵༈͜௄dܝԸ೯ତʘՉ˼ᔼᐕ
͜௄̙ఊዹΎᐏࡘਖ਼л 17dႊ͊೯ତʘᔼᐕ͜௄᙮׵͊ҁϓ೯׼dʔίʊ
ࣨ ࡘ͜௄ਖ਼лᛆʘᇍఖ 18f˸Ң਷ୋ 252045 ໮ʿୋ 310274 ໮೯׼ਖ਼лމ
ԷdՇࣩޫ˸঍໗९ƹ1 ݺމ׌ʷيdՉʕɓਖ਼лطڷ ᐕ઻Аसߧה˜;
дʘ͜௄™d̤ɓਖ਼лطމᐕ઻Аसʘ˜ڜ ᖟ೯͛઻Аषसʘ͜௄™d